BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29228732)

  • 1.
    Negi V; Vishwakarma BA; Chu S; Oakley K; Han Y; Bhatia R; Du Y
    Oncotarget; 2017 Nov; 8(58):98853-98864. PubMed ID: 29228732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10.
    Oakley K; Han Y; Vishwakarma BA; Chu S; Bhatia R; Gudmundsson KO; Keller J; Chen X; Vasko V; Jenkins NA; Copeland NG; Du Y
    Blood; 2012 Jun; 119(25):6099-108. PubMed ID: 22566606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
    Nakahara F; Sakata-Yanagimoto M; Komeno Y; Kato N; Uchida T; Haraguchi K; Kumano K; Harada Y; Harada H; Kitaura J; Ogawa S; Kurokawa M; Kitamura T; Chiba S
    Blood; 2010 Apr; 115(14):2872-81. PubMed ID: 19861684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia stem cells.
    Jamieson CH
    Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
    Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
    Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
    Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis.
    Andrews DF; Collins SJ
    Leukemia; 1987 Oct; 1(10):718-24. PubMed ID: 3312834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.
    Nguyen N; Vishwakarma BA; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
    Oncotarget; 2016 Dec; 7(52):86300-86312. PubMed ID: 27863435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis.
    Sirard C; Lapidot T; Vormoor J; Cashman JD; Doedens M; Murdoch B; Jamal N; Messner H; Addey L; Minden M; Laraya P; Keating A; Eaves A; Lansdorp PM; Eaves CJ; Dick JE
    Blood; 1996 Feb; 87(4):1539-48. PubMed ID: 8608245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
    Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
    Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia.
    Prinzhorn W; Stehle M; Kleiner H; Ruppenthal S; Müller MC; Hofmann WK; Fabarius A; Seifarth W
    Biomark Res; 2016; 4():5. PubMed ID: 26937281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
    Griner LN; Reuther GW
    Cancer Biol Ther; 2010 Nov; 10(10):979-82. PubMed ID: 21084860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Musashi2 translocation as a novel oncogene in myeloid leukemia.
    Spinler K; Hamilton M; Bajaj J; Shima Y; Diaz E; Kritzik M; Reya T
    bioRxiv; 2023 Dec; ():. PubMed ID: 38234720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients.
    Bussolari R; Candini O; Colomer D; Corradini F; Guerzoni C; Mariani SA; Cattelani S; Silvestri C; Pecorari L; Iacobucci I; Soverini S; Fasano T; Martinelli G; Cervantes F; Calabretta B
    Leuk Res; 2007 Feb; 31(2):163-7. PubMed ID: 16797705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biology of CML blast crisis.
    Calabretta B; Perrotti D
    Blood; 2004 Jun; 103(11):4010-22. PubMed ID: 14982876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia blast crisis arises from progenitors.
    Michor F
    Stem Cells; 2007 May; 25(5):1114-8. PubMed ID: 17218393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blast crisis Ph+ chronic myeloid leukemia with NUP98/HOXA13 up-regulating MSI2.
    Di Giacomo D; Pierini V; Barba G; Ceccarelli V; Vecchini A; Mecucci C
    Mol Cytogenet; 2014; 7():42. PubMed ID: 24971156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.